Salute e Benessere

Director/PDMR Shareholding

DXS INTERNATIONAL PLC(AQSE: DXSP)Notification of Director / PDMR DealingDXS INTERNATIONAL PLC The Board of DXS International plc (the “Company” or “DXSP), the AQSE Growth Market quoted clinical decision support developer and supplier of clinical decision support systems, has received notification that on 31 January, Mr Bob Sutcliffe, the Chairman, purchased 30,000 Ordinary Shares in the Company at a price of 2.89p per share.Following this transaction Mr Sutcliffe and his...
Nasdaq GlobeNewswire
10/02/2025

ANTARES VISION GROUP SIGNS LANDMARK AGREEMENT WITH THE MINISTRY OF HEALTH OF…

As part of this agreement, Antares Vision Group will establish a nationwide pharmaceutical traceability and verification system, ensuring greater visibility and security across the entire supply chain. Mandatory registration for all supply chain participants will commence in the second half of 2025, with further details to be announced by the Ministry of Health ofGuinea-Bissau. TransformingGuinea-Bissau'sPharmaceutical Landscape With this initiative,Guinea-Bissauwill...
PR Newswire
10/02/2025

Philips, World Bank, and Ukraine Ministry of Health announce successful…

Groundbreaking program that provides technology and training is reducing the impact of stroke, one of the leading causes of death and disability, by establishing an advanced nationwide acute stroke treatment networkAmsterdam, the Netherlands and Kyiv, Ukraine –Royal Philips(NYSE: PHG, AEX: PHIA), a global leader in health technology, in collaboration with the World Bank and Ukraine's Ministry of Health (MOH), today announced a nationwide initiative to modernize stroke and...
Nasdaq GlobeNewswire
10/02/2025

GENFIT Announces Final Terms for Dual Proposal to the 2025 OCEANEs Holders

In conjunction with the royalty financing deal with HealthCare Royalty (HCRx) announced on January 30, 2025, GENFIT will request the consent of the holders of 2025 OCEANEs and proposes : to repurchase the 2025 OCEANEs at EUR 32.00 per bond from interested bondholders, or alternativelyto pay a consent fee of EUR 0.60 per bond still outstanding after the upcoming bondholder meeting and cancellation of the repurchased 2025 OCEANEsBoth proposals are subject to approval of the...
Nasdaq GlobeNewswire
10/02/2025

Santhera Announces Chief Financial Officer Transition with Appointment of…

Catherine Isted, an experienced healthcare CFO with over 25 years in life sciences, appointed as CFO effective February 24, 2025Current CFO Andrew Smith to step down after five years with Santhera, and will support an orderly transition Pratteln, Switzerland, February 10, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Catherine Isted as Chief Financial Officer (CFO), effective February 24, 2025. She succeeds Andrew Smith, who, after five years at Santhera...
Nasdaq GlobeNewswire
10/02/2025

Daewoong Pharmaceutical, a leading healthcare company in Korea, has launched its…

Leveraging NABOTA's superior quality and safety, Daewoong Pharmaceutical aims to meet the needs of patients in Saudi Arabia and the wider Middle Eastern region while expanding its market share. Daewoong Pharmaceutical's premium high-purity botulinum toxin, produced using the patented 'HI-PURE™ Technology' and advanced vacuum drying processes, received FDA approval in 2019, making it the first Asian-manufactured botulinum toxin to gain such recognition. NABOTA boasts a high-purity composition…
PR Newswire
10/02/2025

2025 Singclean Global Aesthetic Master Symposium Debuted in France

The grand opening of the Singclean Global Aesthetic Master Symposium was honored to welcome renowned international plastic surgeon Dr.Matt Stefanelliand German plastic surgeon Dr. Sercan. Dr. Sercan shared his insights on the evolving trends in Western aesthetic medicine, highlighting the increasing demand for multi-site, multi-dose procedures and the increasing number of male patients seeking aesthetic treatments. The Symposium was also featured by a presentation by Dr. You Xi,...
PR Newswire
10/02/2025

BIOVAXYS ANNOUNCES EXTENSION OF PRIVATE PLACEMENT CLOSING DATE

In order to provide sufficient time for additional investors to participate in the Private Placement, the Company has extended the closing date of its fourth and final tranche (the "Final Tranche") of the Private Placement previously scheduled for February 7, 2025, to on or about, but no later than, February 14, 2025. The Company intends to use the net proceeds of the Final Tranche for working capital. All securities to be issued pursuant to the Final Tranche will be subject to a…
PR Newswire
08/02/2025

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial…

Attachments Notification of managers' transaction - Anthony RosenbergNotification of managers' transaction - Pall JohanessonNotification of managers' transaction - Riad SherifNotification of managers' transaction - Sylvia Cheung
Nasdaq GlobeNewswire
08/02/2025

Pharming Technologies B.V. declares unconditional and completes the recommended…

This press release is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the...
Nasdaq GlobeNewswire
07/02/2025

Cochlear Implants Market to Hit USD 4.73 Billion by 2030 with 9.2% CAGR |…

Browse in-depth TOC on "Cochlear Implants Market" Browse in-depth TOC on "Cochlear Implants Market" 207 - Tables 46 - Figures 215 - Pages A cochlear implant is an advanced electronic device used to provide a sense of sound to individuals with profound hearing loss or severe deafness. It consists of an external component worn behind the ear and an internal component surgically implanted under the skin. Based on component type, the global cochlear implants market can be...
PR Newswire
07/02/2025

Implantica presents the Year-end Report (Q4 2024) on February 14 at 15:00 CET

If you wish to participate via webcast, please use the following link: If you wish to participate via webcast, please use the following link: If you wish to participate via teleconference, please register on the link below. After registration, you will be provided the phone number and a conference ID to access the conference. Speakers: For further information, please contact: Nicole Pehrsson, Investor Relations Telephone (CH): +41 (0)79 335 09 49nicole.pehrsson@implantica...
PR Newswire
07/02/2025

Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives…

Trading in Novo Nordisk shares by board members, executives and associated persons Bagsværd, Denmark, 7 February 2025— This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company's board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.The company's board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given...
Nasdaq GlobeNewswire
07/02/2025

New England Journal of Medicine publishes new data for Roche's Gazyva/Gazyvaro…

Nearly half of patients on Gazyva/Gazyvaro plus standard therapy achieved a complete renal response (CRR), with a statistically significant and clinically meaningful improvement, compared to standard treatment alone 1 Analysis showed consistent CRR benefit across patient subgroups, highlighting potential to treat a broad patient population with high unmet need 1 Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody in a phase III study to demonstrate CRR benefit, 1which is...
Nasdaq GlobeNewswire
07/02/2025

Novo Nordisk A/S: Once-weekly Mim8 is well-tolerated and efficacious in children…

Phase 3 FRONTIER3 interim analysis data presented at EAHAD 2025 showed that 74.3% of children on once-weekly Mim8 prophylaxis experienced zero treated bleeds Bagsværd, Denmark, 7 February 2025– Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed once-weekly prophylaxis treatment (regular treatment to prevent prolonged and spontaneous bleeding)...
Nasdaq GlobeNewswire
07/02/2025

Dedicare's Year-end Report 1 January - 31 December 2024: Continued weak progress…

Performance measures Performance measures Dividend Dedicare's Board of Directors has proposed an ordinary dividend ofSEK 2.50per share (6.50), corresponding toSEK 23.9 million(62.2) for the financial year 2024. The group's dividend policy is that the annual dividend should amount to at least 50 percent of consolidated net profit over a business cycle. The proposed dividend corresponds to 50.8 percent (56.3) of net profit for the year. Dedicare's equity/assets ratio amounts...
PR Newswire
07/02/2025

SKF continues the preparations for the separation of its Automotive business…

SKF is seeking the consent as a matter of prudence and in order to avoid any potential uncertainty in the future. SKF does not consider that there has been an event of default under any series of the notes. SKF is seeking the consent as a matter of prudence and in order to avoid any potential uncertainty in the future. SKF does not consider that there has been an event of default under any series of the notes. As previously communicated, SKF considers that the contemplated spin-off of its...
PR Newswire
07/02/2025

Press Release: Execution of a share buyback agreement for up to €2 billion

Execution of a share buyback agreement for up to €2 billionParis, February 7, 2025.OnJanuary 30, 2025, Sanofi announced its intention to execute a share buyback program in 2025 of €5 billion, preferably through block trades and in the open market with the purpose of cancellation.A first tranche of this program was announced onFebruary 3, 2025, and executed on February 5, 2025, for an amount of €3 billion, through an off-market block trade with the long-standing shareholder...
Nasdaq GlobeNewswire
07/02/2025

Framatome and IBA to partner to develop an Astatine-211 Cyclotron Network in…

Louvain-La-Neuve, Belgium, and Paris, France, 7 February 2025- Framatome, an international leader in nuclear energy committed to developing products and services for the healthcare industry, and IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and the leading provider of radiopharmaceutical production solutions, today announced they have signed a Memorandum Of Understanding to start a strategic partnership aimed at advancing industrial-scale...
Nasdaq GlobeNewswire
07/02/2025

Global Airway Clearance Devices for Cystic Fibrosis Market to Show Positive…

Key Takeaways from the Airway Clearance Devices for Cystic Fibrosis Market Report Key Takeaways from the Airway Clearance Devices for Cystic Fibrosis Market Report To read more about the latest highlights related to the airway clearance devices for cystic fibrosis market, get a snapshot of the key highlights entailed in theGlobal Airway Clearance Devices for Cystic Fibrosis Market Report Airway Clearance Devices for Cystic Fibrosis Overview Airway clearance devices play a...
PR Newswire
06/02/2025

GENFIT Outlines Anticipated New Clinical Trial Initiations, Development…

2 new ACLF clinical trials expected to initiate in 1Q253 clinical data readouts expected by year-end 2025 across the ACLF pipeline, including on-going UNVEIL-IT® Phase 2 trialData of on-going Phase 1b also expected by year-end 2025 for GNS561/trametinib in KRAS-mutated cholangiocarcinoma, to support dose selection for Phase 2 Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), February 6, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a...
Nasdaq GlobeNewswire
06/02/2025

CARBIOS is pleased that the European Commission has authorised the 'Circular…

A significant step towards the payment to CARBIOS of grant subsidies validated by ADEME and the Grand Est Region, totalling €42.5m, for the construction of the CARBIOS Longlaville biorecycling plant in France CARBIOS has reaffirmed its objective of building its PET biorecycling plant in Longlaville once the additional public and private financing, in particular non-dilutive financing, has been securedClermont-Ferrand (France), 6 February 2025 (18:30 CET).CARBIOS,...
Nasdaq GlobeNewswire
06/02/2025

Shareholding declaration Valneva SE - January 2025

VALNEVADeclaration of shares and voting rightsJanuary 31, 2025__________________________________________________________________________________________Company name: VALNEVA Registered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France) Regulated market of Euronext Paris - Compartment B Declaration date: February 6, 2025 Number ofsharescomposing theshare capital of ValnevaTotal numberof voting rights including suspended voting rights*...
Nasdaq GlobeNewswire
06/02/2025

Ipsen - January 2025 - Monthly information relative to the total number of…

Monthly information relative to the total number of voting rightsand shares composing the share capital(in accordance with Article L.233-8 II of the French Commercial Code andArticle 223-16 of the General Regulation of theAutorité des Marchés Financiers ) Market: Euronext ParisISIN Code: FR 0010259150 LEI: 549300M6SGDPB4Z94P11 DateTotal number of shares composing the share capitalTotal number of voting rights(1) 31 January 202583,814,526Gross total*...
Nasdaq GlobeNewswire
06/02/2025
Altri  Comunicati